You are here: All Products  > Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor

Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products